inhibiting braf/egfr/mek for colorectal cancer | oncotarget
Published 10 months ago • 74 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
6:27
targeting braf and mek in colorectal cancer
-
3:51
combining braf, mek and egfr inhibition in mcrc
-
47:45
resistance in braf and kras mutant cancers - by ryan corcoran, md, phd
-
29:45
keynote lecture 4: the braf pathway in crc?
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
2:01
clarifying the mechanism of egfr inhibition in kras g13d colorectal cancer
-
1:22
braf mutations and mek inhibitors
-
22:10
novel agents and targets in colorectal cancer
-
4:54
case 1: braf-mutated metastatic colorectal cancer
-
1:36
rechallenge with egfr inhibitors in ctdna ras/braf wt refractory mcrc
-
0:58
kras g12c inhibitors for gi cancer
-
20:52
what is the optimal therapy for braf mutant metastatic colorectal cancer?
-
4:44
braf testing in colorectal cancer
-
2:21
editorial - braf mutation in colorectal cancer: an enigmatic target
-
1:20
jeffrey a. meyerhardt, md, considers the beacon study in braf mutated metastatic colorectal cancer
-
0:33
cetuximab - erbitux - in a nutshell.
-
2:33
braf mutations in colorectal cancer
-
1:26
novel treatment strategies for braf v600e-mutant nsclc
-
4:07
understanding resistance to combined braf and mek inhibiton in melanoma and the significance of cdk4